drugset / Trial / NCT06281158
A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, open-label, nonrandomized, single-dose study in healthy male participants to investigate the absorption, metabolism and excretion of DNL343.
Timeline
- Start
- 2024-03-01
- Primary completion
- 2024-04-30
- Completion
- 2024-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EVETIFATOR | Small molecule | — | Oral |
Indications
No indication recorded.